These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3406049)

  • 41. Nonadherence in bipolar disorder patients: A 14-year retrospective study.
    Narayanan D; Jith A; Bansal R
    Indian J Psychiatry; 2020; 62(3):290-294. PubMed ID: 32773872
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antidepressant adherence: are patients taking their medications?
    Sansone RA; Sansone LA
    Innov Clin Neurosci; 2012 May; 9(5-6):41-6. PubMed ID: 22808448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What Can Be Learned From Nonadherent Patients to Promote the Health of Populations?
    Galea S
    JAMA Health Forum; 2024 Aug; 5(8):e243025. PubMed ID: 39088202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lithium education programme.
    Douzenis A; Brener N
    Br J Psychiatry; 1991 Jul; 159():157-8. PubMed ID: 1888964
    [No Abstract]   [Full Text] [Related]  

  • 45. Does Cocaine Use Increase Medication Noncompliance in Bipolar Disorders? A United States Nationwide Inpatient Cross-Sectional Study.
    Anugwom GO; Oladunjoye AO; Basiru TO; Osa E; Otuada D; Olateju V; Babalola S; Oladunjoye O; Yee MR; Espiridion ED
    Cureus; 2021 Jul; 13(7):e16696. PubMed ID: 34466326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reasons for lithium discontinuation in men and women with bipolar disorder: a retrospective cohort study.
    Öhlund L; Ott M; Oja S; Bergqvist M; Lundqvist R; Sandlund M; Salander Renberg E; Werneke U
    BMC Psychiatry; 2018 Feb; 18(1):37. PubMed ID: 29415689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment-adherence in bipolar disorder: A patient-centred approach.
    Chakrabarti S
    World J Psychiatry; 2016 Dec; 6(4):399-409. PubMed ID: 28078204
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.
    Fountoulakis KN; Yatham L; Grunze H; Vieta E; Young A; Blier P; Kasper S; Moeller HJ
    Int J Neuropsychopharmacol; 2017 Feb; 20(2):121-179. PubMed ID: 27816941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-Compliance and Related Factors in Patients With Bipolar I Disorder: A Six Month Follow-Up Study.
    Azadforouz S; Shabani A; Nohesara S; Ahmadzad-Asl M
    Iran J Psychiatry Behav Sci; 2016 Jun; 10(2):e2448. PubMed ID: 27803718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review.
    Levin JB; Krivenko A; Howland M; Schlachet R; Sajatovic M
    CNS Drugs; 2016 Sep; 30(9):819-35. PubMed ID: 27435356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The neurocognitive functioning in bipolar disorder: a systematic review of data.
    Tsitsipa E; Fountoulakis KN
    Ann Gen Psychiatry; 2015; 14():42. PubMed ID: 26628905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlates of attitudes towards mood stabilizers in individuals with bipolar disorder.
    Chang CW; Sajatovic M; Tatsuoka C
    Bipolar Disord; 2015 Feb; 17(1):106-12. PubMed ID: 24974829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study.
    Jeong JH; Bahk WM; Woo YS; Seo HJ; Hong SC; Jon DI; Min KJ; Yoon BH
    Neuropsychiatr Dis Treat; 2013; 9():197-204. PubMed ID: 23431086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder.
    Sajatovic M; Levin J; Tatsuoka C; Micula-Gondek W; Fuentes-Casiano E; Bialko CS; Cassidy KA
    Bipolar Disord; 2012 May; 14(3):291-300. PubMed ID: 22548902
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment - Moderate dose Use Study (LiTMUS) for bipolar disorder.
    Sylvia LG; Reilly-Harrington NA; Leon AC; Kansky CI; Ketter TA; Calabrese JR; Thase ME; Bowden CL; Friedman ES; Ostacher MJ; Iosifescu DV; Severe J; Keyes M; Nierenberg AA
    Clin Trials; 2012 Feb; 9(1):94-101. PubMed ID: 22076437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Behavioral therapies for co-occurring substance use and mood disorders.
    Carroll KM
    Biol Psychiatry; 2004 Nov; 56(10):778-84. PubMed ID: 15556123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate.
    Dilsaver SC; Swann AC; Shoaib AM; Bowers TC
    J Psychiatry Neurosci; 1993 Mar; 18(2):61-6. PubMed ID: 8461283
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lithium. Current status in psychiatric disorders.
    Peet M; Pratt JP
    Drugs; 1993 Jul; 46(1):7-17. PubMed ID: 7691509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders.
    Maj M; Pirozzi R; Kemali D
    Psychopharmacology (Berl); 1989; 98(4):535-8. PubMed ID: 2505295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adherence to lithium prophylaxis: I. Clinical predictors and patient's reasons for nonadherence.
    Maarbjerg K; Aagaard J; Vestergaard P
    Pharmacopsychiatry; 1988 May; 21(3):121-5. PubMed ID: 3406049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.